Clinical Research Directory

Inclusion Criteria- 1. Age ≥ 18 years. 2. Critically ill adult requiring ICU admission due to severe community acquired pneumonia (CAP), defined by ≥1 major criterion or ≥3 minor criteria (IDSA/ATS): * Major: respiratory failure requiring mechanical ventilation OR septic shock requiring vasopressors. * Minor: tachypnea (RR ≥ 30), PaO2/FiO2 ≤ 200, multilobar infiltrates, new confusion/disorientation, BUN ≥ 20 mg/dL, platelet count \< 100,000/µL, core temperature \< 36.0°C, hypotension requiring aggressive fluid resuscitation. 3. Hospital admission with diagnosis of CAP within 72 hours. 4. Lymphopenia: absolute lymphocyte count (ALC) \< 1,500/µL (not secondary to chemotherapy). 5. Receiving antibiotics for CAP (at least one dose since ICU admission). 6. Informed consent obtainable from participant or legally authorized representative. Exclusion Criteria- 1. Hematologic malignancy (e.g., active leukemia or lymphoma not in remission). 2. Post CAR T therapy or hematopoietic cell transplant for ALL, NHL, or multiple myeloma \< 3 months prior to enrollment. 3. Current diagnosis of cytokine release syndrome. 4. Receiving colony stimulating factors (e.g., G CSF). 5. Clinical history or imaging suggesting aspiration of gastric contents. 6. Advanced dementia or prolonged bedridden status. 7. Pregnancy or breastfeeding. 8. High dose immunosuppressive therapy at baseline (e.g., \> 0.5 mg/kg prednisone or equivalent). (Low dose corticosteroids for septic shock/ARDS per SOC permitted.) 9. Uncontrolled autoimmune or inflammatory disease requiring immunosuppressive therapies. 10. Life expectancy \< 24-48 hours or moribund condition despite care (investigator judgment). 11. Active uncontrolled bleeding or intracerebral hemorrhage. 12. Known hypersensitivity to ingredients used in the cell product formulation (e.g., DMSO). 13. Treated by antibiotics for the current respiratory infection for more than seven days at time of hospitalization (unless culture/sensitivity indicates resistant organism to administered antibiotics). 14. Known active viral hepatitis A, B, or C. 15. Investigator judgment that participation is not in the participant's best interest or participant is unsuitable for enrollment.